Diagnosis and monitoring of HCV infection using the cobas ® HCV test for use on the cobas ® 6800/8800 systems
Open Access
- 1 May 2018
- journal article
- research article
- Published by Elsevier BV in Journal of Clinical Virology
- Vol. 102, 63-69
- https://doi.org/10.1016/j.jcv.2018.02.017
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling studyThe Lancet Gastroenterology & Hepatology, 2017
- The cobas® 6800/8800 System: a new era of automation in molecular diagnosticsExpert Review of Molecular Diagnostics, 2016
- All‐oral direct‐acting antiviral therapy in HCV‐advanced liver disease is effective in real‐world practice: observations through HCV‐TARGET databaseAlimentary Pharmacology & Therapeutics, 2016
- Hepatitis C virus NS3/4a protease inhibitorsCurrent Opinion in Pharmacology, 2016
- Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirinJournal of Hepatology, 2014
- Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trialThe Lancet, 2014
- Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis CThe New England Journal of Medicine, 2013
- Peginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV Genotype 2 or 3The New England Journal of Medicine, 2007
- Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3The New England Journal of Medicine, 2005